ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / SCLX / insiders
DYAI (31) ABOS (33) PLUR (34) JSPR (36) ⌘ Pro Terminal β†’

Scilex Holding Company (SCLX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.87 +1.08% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.87

Scilex Holding Company (SCLX) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $15.7M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SCLX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SCLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Scilex Holding Company (NASDAQ: SCLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.87 (+1.08% 1D, market cap $15.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, SCLX ranks #470 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SCLX compare to DYAI and ABOS in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and ABOS (Acumen Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SCLX?
β–Ό

Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.87 (+0.00%)🧬 Disciplined Float (-0.40% YoY Shares)βš™οΈ Cash Engine: 12/20 (C-) β€’ 12.2% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (40/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510040
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D-
Cash (12)Whales (3)SEC (8)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-8% Base Target
$18 Bull$2 Base$1 Bear
πŸ“¬ FREE SCLX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SCLX)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
πŸ” WHY SCLX SCORES 40/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+12/20 pts (30% of score)

SEC XBRL FY 2025 (10-K): 12.2% FCF Margin ($3.7M FCF) & 415.8% Gross Margin

β–² #2 Bullish Driver: Insider Conviction & Share Dilution+9/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 45% Net Buy β€’ Disciplined Float (-0.40% YoY Shares)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
48
Grade D$2.88-12.2% Next Q
Q2 (-2Q)
45
Grade D$2.53-19% Next Q
Q3 (-1Q)
43
Grade D$2.05-8.8% Next Q
Current
40
Grade D-$1.87-7.4% Hist 90D Ξ±
Trajectory: D (48) β†’ D- (40)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a SCLX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While SCLX currently carries a cautious 40/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.02) and Max Pain ($1.96) forces dealer call-delta covering toward $17.65.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SCLXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSCLX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

SCLX Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SCLX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SCLX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCLX)

  • βœ“Walkthrough of SCLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
SCLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.05%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $2.06H $2.06L $1.85C $1.87VOL 49.9K
RES: $8.73SUP: $1.69SMA50: $4.02SMA200: $5.26
$11.03$8.54$6.04$3.55$1.06RES $8.73SUP $1.69$1.872026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ SCLX Butterfly Map β†’ + Track SCLX β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -46.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SCLX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SCLX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SCLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCLX)

Health Care Rank #470 of 1015 βš”οΈ DYAI vs SCLX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (SCLX vs. DYAI, ABOS, PLUR, JSPR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Scilex Holding Company (SCLX) ranks #470 by composite RQD confidence (40/100, grade D-) and #849 by equity capitalization ($15.7M). Within this direct 5-issuer industry benchmark cohort, SCLX leads on earnings valuation at N/A trailing P/E, while SCLX leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. SCLX currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SCLX ACTIVE
Scilex Holding Company
D- 40/100 β€” 96.0% -35.0% +1.08% $15.7M Benchmark Subject
DYAI
Dyadic International Inc.
E 31/100 β€” 24.9% -35.0% -1.10% $15.2M /dyai-vs-sclx β†’
ABOS
Acumen Pharmaceuticals Inc.
E 33/100 β€” β€” -35.0% +14.09% $15.2M /abos-vs-sclx β†’
PLUR
Pluri Inc.
E 34/100 β€” 49.0% -35.0% -3.23% $16.7M /plur-vs-sclx β†’
JSPR
Jasper Therapeutics Inc.
D- 36/100 β€” β€” -35.0% -2.35% $17.3M /jspr-vs-sclx β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001820190 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scilex Holding Company (SCLX) reported GAAP revenue of $30.3M (-46.5% vs. FY2024 revenue of $56.6M , and -35.3% cumulative change since FY2023) , GAAP net income of -$374.1M, operating cash flow of $3.8M, and free cash flow of $3.7M (-81.0% YoY). On the balance sheet, SCLX closed FY2025 with $365.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $30.3M -$374.1M $3.8M $3.7M $365.0M β€”
FY2024 (FY) 2024-12-31 $56.6M -$72.8M $19.3M $19.3M $93.0M β€”
FY2023 (FY) 2023-12-31 $46.7M -$114.3M -$20.7M -$20.7M β€” β€”

3. SCLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Scilex Holding Company (NASDAQ: SCLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.87 (+1.08% 1D, market cap $15.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, SCLX ranks #470 in composite RQD confidence.

How does SCLX compare to DYAI and ABOS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and ABOS (Acumen Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCLX?

Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCLX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCLX last traded at $1.87 (+1.08% on volume of 54,938 shares), positioning the stock -53.48% below its 50-day simple moving average ($4.02) and -64.45% below its 200-day simple moving average ($5.26). Across its 52-week range of $1.83 to $16.81, SCLX sits at the 0.3% percentile with a 14-day RSI of 20.9 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.64 to $2.10).

Direct Sub-Reports: SCLX RQD Cockpit SCLX 12M Forecast SCLX Earnings & Move SCLX Dividends & DRIP SCLX Insiders & 13F SCLX Whale Options SCLX Profit Sankey SCLX News & Why
ROARABLE RATING BRIEF β€’ RQD 40/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

SCLX β€” Scilex Holding Company: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Scilex Holding Company (SCLX) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.87 (+1.08% 1D, market capitalization $15.7M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 96.0%, operating margin of -60.0%, and free cash flow yield of 21.05%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Scilex Holding Company (SCLX) is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances)..0B on a rounded basis, while the market data reports $17.5M. β€” describes its products, customers, or revenue model. The source data reports gross margin of 96% alongside operating margin of -60%, indicating a high gross-margin structure with operating losses below that line.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Scilex Holding Company (SCLX) reported $30.3M in annual revenue (up from $56.6M in FY2024, -46.5% YoY) and -$374.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($46.7M revenue, -$114.3M net income) through FY2025, SCLX scaled operating cash flow to $3.8M and free cash flow to $3.7M, backed by $365.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 21.05% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.83 – $16.81 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector classification is Health Care and industry is Biotechnology: Biological Products (No Diagnostic Substances). β€” identifies upstream suppliers, downstream customers, or sector correlations. Because no dependency links are present, second-order bottlenecks cannot be mapped from the source data.

  • Key Question #1: Can SCLX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $30.3M and free cash flow of $3.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SCLX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SCLX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Scilex Holding Company (SCLX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to SCLX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SCLX Bull vs. Bear Conversation Board β€” What's Your Call at $1.87?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SCLX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SCLX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER β€’ Institutional Buy-Side πŸ‚ BULLISH 🎯 Target: $2.35 (+27.0%)
πŸ“Œ Pinned Debate

The 21.05% FCF yield signals cash generation relative to the $2.06 share price despite negative earnings.

The 21.05% FCF yield signals cash generation relative to the $2.06 share price despite negative earnings.. When you look under the hood at SCLX, Fundamental Cash Engine is 12/20 with 96.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $16.81. My 12M target is $2.35.

SectorRotator πŸ‚ BULL

@DeepValue_CFA Agree on the RQD 40/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.85 and keeping dry powder in case we test $1.72.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $1.48 (-20.0%)
Spot @ $1.85

A -35% ROIC and a -60% net margin, with FY 2025 net loss of -$374.1M against $5.0M cash, leave the balance sheet highly vulnerable.

A -35% ROIC and a -60% net margin, with FY 2025 net loss of -$374.1M against $5.0M cash, leave the balance sheet highly vulnerable.. Look at the math on SCLX: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $1.63 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%